Journal
LABORATORY MEDICINE
Volume 50, Issue 2, Pages 150-157Publisher
OXFORD UNIV PRESS
DOI: 10.1093/labmed/lmy055
Keywords
HAR1A; HAR1B; hepatocellular carcinoma; expression; survival; RT-qPCR
Categories
Funding
- Zhejiang Medical and Health Science and Technology Project [2015KYB369]
- Ruian Scientific and Technological Innovation Special Fund [MS2015014, MS2015012, MS2015020]
Ask authors/readers for more resources
Objective To determine the clinical relevance of long noncoding RNA (lncRNA) HAR1A and HAR1B expression in hepatocellular carcinoma (HCC). Methods In this study, we enrolled 50 cases of chronic hepatitis B (CHB) without cirrhosis, 50 cases of CHB and liver cirrhosis (LC), and 100 cases of HBV and HCC. The expression profiles of lncRNA HAR1A and HAR1B were analyzed using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Results The expression levels of HAR1A and HAR1B were significantly lower in the HCC group, compared with the CHB and LC groups (P <.01). HAR1A and HAR1B were negatively associated with histologic grade and TNM (tumor/nodes/metastasis) stage (all P <.05). Univariable multivariable analysis showed that decreased HAR1A (HR = 0.753, P = .02) and HAR1B (HR = 0.551, P = .01) levels were independent predictors for shorter overall survival (OS) in HCC. Conclusion Decreased HAR1A and HAR1B expression in HCC indicates poor prognosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available